These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

446 related items for PubMed ID: 15652759

  • 1. Involvement of doxorubicin-induced Fas expression in the antitumor effect of doxorubicin on Lewis lung carcinoma in vivo.
    Yoshimoto Y, Kawada M, Ikeda D, Ishizuka M.
    Int Immunopharmacol; 2005 Feb; 5(2):281-8. PubMed ID: 15652759
    [Abstract] [Full Text] [Related]

  • 2. Fas signal promotes lung cancer growth by recruiting myeloid-derived suppressor cells via cancer cell-derived PGE2.
    Zhang Y, Liu Q, Zhang M, Yu Y, Liu X, Cao X.
    J Immunol; 2009 Mar 15; 182(6):3801-8. PubMed ID: 19265159
    [Abstract] [Full Text] [Related]

  • 3. Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively.
    Hashimoto W, Osaki T, Okamura H, Robbins PD, Kurimoto M, Nagata S, Lotze MT, Tahara H.
    J Immunol; 1999 Jul 15; 163(2):583-9. PubMed ID: 10395644
    [Abstract] [Full Text] [Related]

  • 4. Antitumor effects are produced by forced expression of membrane-bound but not soluble Fas ligand in murine lung carcinoma cells.
    Tada Y, O-Wang J, Seimiya M, Takiguchi Y, Tatsumi K, Kuriyama T, Tagawa M.
    Anticancer Res; 2002 Jul 15; 22(2A):831-6. PubMed ID: 12014659
    [Abstract] [Full Text] [Related]

  • 5. Addressing the "Fas counterattack" controversy: blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo.
    Ryan AE, Shanahan F, O'Connell J, Houston AM.
    Cancer Res; 2005 Nov 01; 65(21):9817-23. PubMed ID: 16267003
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. FR901228 induces tumor regression associated with induction of Fas ligand and activation of Fas signaling in human osteosarcoma cells.
    Imai T, Adachi S, Nishijo K, Ohgushi M, Okada M, Yasumi T, Watanabe K, Nishikomori R, Nakayama T, Yonehara S, Toguchida J, Nakahata T.
    Oncogene; 2003 Dec 18; 22(58):9231-42. PubMed ID: 14647441
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Induction of antitumor immunity with Fas/APO-1 ligand (CD95L)-transfected neuroblastoma neuro-2a cells.
    Shimizu M, Fontana A, Takeda Y, Yagita H, Yoshimoto T, Matsuzawa A.
    J Immunol; 1999 Jun 15; 162(12):7350-7. PubMed ID: 10358186
    [Abstract] [Full Text] [Related]

  • 10. In vivo rejection of tumor cells dependent on CD8 cells that kill independently of perforin and FasL.
    Lee SH, Bar-Haim E, Machlenkin A, Goldberger O, Volovitz I, Vadai E, Tzehoval E, Eisenbach L.
    Cancer Gene Ther; 2004 Mar 15; 11(3):237-48. PubMed ID: 14739939
    [Abstract] [Full Text] [Related]

  • 11. Fas ligand-expressing tumors induce tumor-specific protective immunity in the inoculated hosts but vaccination with the apoptotic tumors suppresses antitumor immunity.
    Tada Y, O-Wang J, Wada A, Takiguchi Y, Tatsumi K, Kuriyama T, Sakiyama S, Tagawa M.
    Cancer Gene Ther; 2003 Feb 15; 10(2):134-40. PubMed ID: 12536202
    [Abstract] [Full Text] [Related]

  • 12. Ultraviolet light-induced immune tolerance is mediated via the Fas/Fas-ligand system.
    Schwarz A, Grabbe S, Grosse-Heitmeyer K, Roters B, Riemann H, Luger TA, Trinchieri G, Schwarz T.
    J Immunol; 1998 May 01; 160(9):4262-70. PubMed ID: 9574528
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Up-regulation of Fas and the costimulatory molecules B7-1 and B7-2 on peripheral lymphocytes in autoimmune B6/gld mice.
    Weintraub JP, Eisenberg RA, Cohen PL.
    J Immunol; 1997 Oct 15; 159(8):4117-26. PubMed ID: 9379003
    [Abstract] [Full Text] [Related]

  • 16. Fas/Apo-1 (CD95)-mediated apoptosis of neutrophils with Fas ligand (CD95L)-expressing tumors is crucial for induction of inflammation by neutrophilic polymorphonuclear leukocytes associated with antitumor immunity.
    Shimizu M, Fontana A, Takeda Y, Yoshimoto T, Tsubura A, Matsuzawa A.
    Cell Immunol; 2001 Jan 10; 207(1):41-8. PubMed ID: 11161452
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity.
    Mitsiades N, Yu WH, Poulaki V, Tsokos M, Stamenkovic I.
    Cancer Res; 2001 Jan 15; 61(2):577-81. PubMed ID: 11212252
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.